Cancer Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)

Cancer Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)

  • March 2020 •
  • 120 pages •
  • Report ID: 5881440 •
  • Format: PDF
Certain factors that are driving the market growth include the increased incidence of cancer, globally, and higher acceptance of treatments for cancer in the developing regions, the paradigm shift in healthcare, from disease diagnosis to risk assessment or early diagnosis, and increasing usage of biomarkers in drug development.

- Globally, cancer is one of the leading causes of death. In 2015, it accounted for 8.8 million deaths, causing nearly one in every six deaths.
- The disease witnessed significant growth in the last few decades, and it is expected to grow rapidly over the forecast period.
- The World Health Organization (WHO) estimates the rate of cancer number to increase to 70% over the next two decades.
- Additionally, the increased burden of several lifestyle disorders is also expected to drive the market, as biomarkers play a vital role in risk assessment, early diagnosis, and effective monitoring of treatment.
- According to the WHO, almost 70% of deaths from cancer occur in low- and middle-income countries, and only one in five low- and middle-income countries has the necessary data to drive its cancer policy.
- As data is being generated aggressively in the healthcare sector, a few developing countries have surpassed the lack of data, and it is likely to become so in the remaining countries as well. This augmentation of data is expected to provide the basis for any national policy on cancer. In turn, this factor may possibly lead to an increase in the percentage of people opting for cancer treatment. Thus, the increase in demand in the low- and middle-income countries is projected to boost the cancer biomarkers market.

Key Market Trends
Prostate Cancer is Expected to Hold Significant Market Share

Prostate cancer is the second-most common form of cancer that affects men, worldwide. As per the American Cancer Society, in 2018, the United States witnessed around 164,690 new cases of prostate cancer, causing over 26,430 deaths. About 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. In order to tackle such challenges, extensive research in the field of diagnostics has been undertaken. The popular biomarker, Prostate Specific Antigen (PSA), was introduced in the late 1980s, and has guided prostate cancer diagnosis for over 20 years. The next generation of prostate cancer biomarkers has introduced new assays in serum and urine, which are expected to replace PSA. Moreover, with such a high prevalence rate of prostate cancer across the world, the demand for diagnostic devices is sure to rise, in turn, leading to the growth of this segment in the years to come.

North America Dominates the Market and is Expected to do the Same Over the Forecast Period

The United States witnessed a considerable rise in the number of cancer patients. Prostate and breast cancers are the most prevalent forms of cancer in the region. According to the estimates of the American Cancer Society, in the United States, around 220,800 new cases of prostate cancer were diagnosed and about 27,540 deaths occurred due to this cancer, in 2015. Additionally, it is estimated that, currently, there are nearly three million American men suffering from prostate cancer. In 2015, an estimated 246,660 new cases of invasive breast cancer and 60,290 additional cases of in-situ breast cancer were diagnosed among women in the United States. The ease in the US government regulations and availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in the use of biomarkers in drug discovery, drug development, detection of specific tumors, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates of cancer.

Competitive Landscape
The cancer biomarkers market is highly competitive and consists of a number of major players. Companies, like 23andMe, Abbott Laboratories Inc., Agilent Technologies, Ambry Genetics, Biomerieux, Celera Corporation (Quest Diagnostics), F. Hoffmann-La Roche Ltd, Hologic Inc., Illumina Inc., and Thermo Fisher Scientific, among others, hold substantial shares in the market.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.